Press Releases
Tower’s latest container available for free demonstrations
Tower Cold Chain’s latest product for smaller pharmaceutical shipments, the KTEvolution container offering protection, security, and visibility in a small box, is now available for demonstration globally, at the company’s Centres of Excellence in the EMEA, APAC and Americas...
Press Releases
Pistoia Alliance Launches New Community of Experts to Use Social Media Insights to Drive Patient-Centric Drug Development
The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has launched a new Community of Experts (CoE) to harness real-world data from social media. The COE aims to develop best practices and...
Press Releases
Malvern Panalytical and Applied Photophysics announce distribution agreement for Protein Stable’s SUPR-DSF
Malvern Panalytical (Malvern, UK) and Applied Photophysics (Leatherhead, UK) have announced their commercial agreement for Malvern Panalytical to distribute Protein Stable’s microplate-based differential scanning fluorimeter, SUPR-DSF, in the United States of America and Canada.
The SUPR-DSF provides researchers with high-throughput...
Press Releases
Tjoapack strengthens its Injectables offering with addition of pre-filled syringes assembly and packaging service
Global pharmaceutical contract packaging organisation (CPO), Tjoapack has invested in a new high-speed packaging line for pre-filled syringes and vials at its production facilities in both Europe and the US.
The recently validated PFS line can pack pre-filled syringes of...
Press Releases
Mural Health Enters the Market to Disrupt Clinical Trial Participant Management Through the Launch of Mural Link Platform
Mural Health Technologies, Inc., a new global provider of clinical trials technology, announced the launch of its new technology platform, Mural Link, which has been built to make it easy to be a participant in global clinical research studies....
Press Releases
Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis
UCB, a global biopharmaceutical company, announced the first presentation of long-term, 52-week data from three Phase 3 studies evaluating the efficacy and safety of bimekizumab in adults with active psoriatic arthritis (PsA) who were biologic-naïve (BE OPTIMAL), in adults...
Press Releases
Clinerion launches its Federated Machine Learning Platform
Clinerion launches its Federated Machine Learning Platform, a global, federated machine learning (ML) platform on its Patient Network Explorer infrastructure, incorporating its global network of partner hospitals. This new platform will enable sophisticated analytics and pattern recognition use cases...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















